During June 13-16, 2024, the European Hematology Association (EHA) 2024 held its Congress in Hybrid format 2024 (EHA2024) in Madrid. This Congress brought together clinicians, researchers, and industry professionals, as it was a unique opportunity to catch up on the latest advances in the field of hematology and connect with colleagues from around the world.
The NANEMIAR project also took advantage of this opportunity with the presence of researchers José Eduardo Salido, Miguel Blanquer, and Valentín Cabañas (Murcian Health Service - Entity Affiliated with the FFIS/IMIB). The NANEMIAR project has been included in the abstract book with a title: DEVELOPMENT OF A TARGETED MRNA-BASED THERAPEUTIC AS A
POTENTIAL NEW TREATMENT FOR BETA-THALASSEMIA (Abstract: PB3238; Abstract Type: Publication Only; Topic: Thalassemias)
DEVELOPMENT OF A TARGETED MRNA-BASED THERAPEUTIC AS A POTENTIAL NEW TREATMENT FOR BETA-THALASSEMIA
Author(s): christophe Lachaud, Jenny vanasbeck-vanderwijst, Miriam Pinilla, Elena Martinez Balsalobre, Miguel Blanquer Blanquer, Eduardo Salido-Fiérrez, Ana Belen Perez Oliva
(Abstract release date: 05/14/24) EHA Library. Perez Oliva A. 06/13/2024; 422004; PB3238
